Elevated Lactate Dehydrogenase Levels Display a Poor Prognostic Factor for Non-Hodgkin’s Lymphoma in Intensive Care Unit: An Analysis of the MIMIC-III Database Combined With External Validation

Qi, Jiaqian; Gu, Chengyuan; Wang, Weijuan; Xiang, Mengqi; Chen, Xiaochen; Fu, Jianhong

doi:10.3389/fonc.2021.753712

Cited by 10 publications

(11 citation statements)

References 22 publications

(12 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The study demonstrated that percentages of EMAP II+CD16+, EMAPII+CD20+, and EMAP II+CD22+ cells Journal of Immunology Research had a significant positive association with elevated LDH levels, which implies the value of EMAP II expression on peripheral blood cells in NHL as a potential biomarker. The reported associations in these data support the correlation between higher levels of EMAP II expression and bad prognosis as elevated LDH levels, which are considered risk factors for poor performance and inferior overall survival [96].…”

Section: Discussionsupporting

confidence: 71%

EMAP II Expression Is Increased on Peripheral Blood Cells from Non-Hodgkin Lymphoma

Saber

2022

Journal of Immunology Research

View full text Add to dashboard Cite

Tumor immune evasion is a lineament of cancer. Endothelial monocyte activating polypeptide-II (EMAP II) has been assumed to impact tumor immune escape significantly. EMAP II was first reported in the murine methylcholanthrene A-induced fibrosarcoma supernatant and identified as a tumor-derived cytokine. This study evaluated EMAP II expression in peripheral blood cells and its association with treatment outcome, lactate dehydrogenase (LDH) levels, and clinical criteria in non-Hodgkin’s lymphoma (NHL) patients. EMAP II expression on different blood cells obtained from the peripheral blood of 80 NHL patients was evaluated by two-color flow cytometry. The study reported that EMAP II expression was significantly increased in peripheral blood cells in patients with NHL compared to normal volunteers ( P < 0.001 ). Additionally, EMAP II expression levels on blood cells decreased in complete remission (CR) while they increased in relapse. This study showed coexpression of EMAP II and CD36 on peripheral lymphocytes in NHL patients but not in healthy controls ( P < 0.001 ). EMAP II expression on blood cells was associated with increased serum LDH levels. Furthermore, the percentages of EMAP II+/CD36+ peripheral lymphocytes were significantly higher in relapse than in CR and healthy controls. Analyses revealed that higher percentages of EMAP II+CD36+ cells were positively correlated with hepatomegaly, splenomegaly, and an advanced (intermediate and high risk) NHL stage. The results assume that EMAP II might be involved in NHL development and pathogenesis.

show abstract

Section: Discussionsupporting

confidence: 71%

EMAP II Expression Is Increased on Peripheral Blood Cells from Non-Hodgkin Lymphoma

Saber

2022

Journal of Immunology Research

View full text Add to dashboard Cite

show abstract

“…IL-19 levels were associated with high LDH levels. High LDH levels were associated with inferior prognosis in lymphoma [ 84 ]. In the current study, patients with extranodal involvement had significantly higher IL-19 levels than patients without extranodal involvement.…”

Section: Discussionmentioning

confidence: 99%

Coexpression of PD-L1/PD-1 with CXCR3/CD36 and IL-19 Increase in Extranodal Lymphoma

Saber

2023

Journal of Immunology Research

View full text Add to dashboard Cite

Many studies have demonstrated that PD-L1/PD-1 signaling is an immune evasion mechanism in tumors. PD-L1/PD-1 coexpression with CXCR3/CD36 in peripheral lymphocytes in lymphoma still needs to be clarified. The current study investigated PD-L1/PD-1 coexpression with CXCR3/CD36 in circulating lymphocytes, serum IL-19 levels, and their correlation with clinical outcome and extranodal involvement in lymphoma. Subjects and Methods. The coexpression of PD-L1/PD-1 with CXCR3/CD36 on circulating lymphocytes was analyzed by flow cytometry in 78 lymphoma patients before and after therapy and in 50 healthy controls. The concentration levels of IL-19 in serum were assessed by an ELISA. Results. PD-L1 and PD-1 were expressed on circulating CXCR3+ and CD36+ lymphocytes in lymphoma and were significantly higher in patients with extranodal involvement than in lymphoma patients without extranodal involvement ( P < 0.001 ). Elevated IL-19 levels were observed in lymphoma patients and increased significantly in extranodal involvement ( P < 0.001 ). High percentages of PD-L1+CXCR3+ and PD-1+CXCR3+ lymphocytes were associated with high LDH levels, hepatomegaly, lymphedema, advanced tumor stage, and recurrence. Furthermore, patients with splenomegaly and generalized lymphadenopathy had high percentages of PD-L1+CXCR3+ lymphocytes. In addition, levels of PD-L1/PD-1 coexpression with CXCR3 and IL-19 were significantly associated with bone marrow, lung, and lymph vessel involvement. Further analysis revealed that high percentages of PD-L1+CD36+ and PD-1+CD36+ lymphocytes were associated with lung and bone marrow involvement. Patients with high levels of PD-L1/PD-1 coexpression with CXCR3 and IL-19 had inferior event-free survival (EFS) compared with that in lymphoma patients with low levels. EFS was decreased in patients with high percentages of PD-L1+CD36+ and PD-1+CD36+ lymphocytes. When using the receiver operating characteristic (ROC) curve, the superiority of IL-19 (area under the curve (AUC): 0.993) and PD-L1+CXCR3+% (AUC: 0.961) to PD-1+CXCR3+% (AUC: 0.805), PD-L1+CD36+% (AUC: 0.694), and PD-1+CD36+% (AUC 0.769) was evident in the diagnosis of extranodal involvement, identifying lymphoma patients with extranodal involvement from patients without extranodal involvement. Conclusions. Coexpression of PD-L1/PD-1 with CXCR3/CD36 in circulating lymphocytes and serum IL-19 levels contributes to poor prognosis and might be potential markers for extranodal involvement in lymphoma.

show abstract

“…Elevated LDH levels have also been mentioned in several studies as a diagnostic value for PCP ( 26 ). However, its predictive value for poor outcomes has rarely been reported ( 16 , 30 ). LDH has special biochemical functions.…”

Section: Discussionmentioning

confidence: 99%

Development and validation of tools for predicting the risk of death and ICU admission of non-HIV-infected patients with Pneumocystis jirovecii pneumonia

Fan

Liang

Chen

et al. 2022

Front. Public Health

View full text Add to dashboard Cite

IntroductionThe mortality rate of non-HIV-infected Pneumocystis jirovecii pneumonia (PCP) is high. This research aimed to develop and validate two clinical tools for predicting the risk of death and intensive care unit (ICU) admission in non-HIV-infected patients with PCP to reduce mortality.MethodsA retrospective study was conducted at Peking Union Medical College Hospital between 2012 and 2021. All proven and probable non-HIV-infected patients with PCP were included. The least absolute shrinkage and selection operator method and multivariable logistic regression analysis were used to select the high-risk prognostic parameters. In the validation, the receiver operating characteristic curve and concordance index were used to quantify the discrimination performance. Calibration curves were constructed to assess the predictive consistency compared with the actual observations. A likelihood ratio test was used to compare the tool and CURB-65 score.ResultsIn total, 508 patients were enrolled in the study. The tool for predicting death included eight factors: age, chronic lung disease, respiratory rate, blood urea nitrogen (BUN), lactate dehydrogenase (LDH), cytomegalovirus infection, shock, and invasive mechanical ventilation. The tool for predicting ICU admission composed of the following factors: respiratory rate, dyspnea, lung moist rales, LDH, BUN, C-reactive protein/albumin ratio, and pleural effusion. In external validation, the two clinical models performed well, showing good AUCs (0.915 and 0.880) and fit calibration plots. Compared with the CURB-65 score, our tool was more informative and had a higher predictive ability (AUC: 0.880 vs. 0.557) for predicting the risk of ICU admission.ConclusionIn conclusion, we developed and validated tools to predict death and ICU admission risks of non-HIV patients with PCP. Based on the information from the tools, clinicians can tailor appropriate therapy plans and use appropriate monitoring levels for high-risk patients, eventually reducing the mortality of those with PCP.

show abstract

Elevated Lactate Dehydrogenase Levels Display a Poor Prognostic Factor for Non-Hodgkin’s Lymphoma in Intensive Care Unit: An Analysis of the MIMIC-III Database Combined With External Validation

Cited by 10 publications

References 22 publications

EMAP II Expression Is Increased on Peripheral Blood Cells from Non-Hodgkin Lymphoma

EMAP II Expression Is Increased on Peripheral Blood Cells from Non-Hodgkin Lymphoma

Coexpression of PD-L1/PD-1 with CXCR3/CD36 and IL-19 Increase in Extranodal Lymphoma

Development and validation of tools for predicting the risk of death and ICU admission of non-HIV-infected patients with Pneumocystis jirovecii pneumonia

Contact Info

Product

Resources

About